396 related articles for article (PubMed ID: 26873369)
1. Dipeptidyl Peptidase (DPP)-4 Inhibitor-Induced Arthritis/Arthralgia: A Review of Clinical Cases.
Mascolo A; Rafaniello C; Sportiello L; Sessa M; Cimmaruta D; Rossi F; Capuano A
Drug Saf; 2016 May; 39(5):401-7. PubMed ID: 26873369
[TBL] [Abstract][Full Text] [Related]
2. Recent patents of dipeptidyl peptidase IV inhibitors.
Mendieta L; Tarrago T; Giralt E
Expert Opin Ther Pat; 2011 Nov; 21(11):1693-741. PubMed ID: 22017411
[TBL] [Abstract][Full Text] [Related]
3. Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.
Li N; Wang LJ; Jiang B; Li XQ; Guo CL; Guo SJ; Shi DY
Eur J Med Chem; 2018 May; 151():145-157. PubMed ID: 29609120
[TBL] [Abstract][Full Text] [Related]
4. Dipeptidyl peptidase IV inhibitors as a potential target for diabetes: patent review (2015-2018).
Hussain H; Abbas G; Green IR; Ali I
Expert Opin Ther Pat; 2019 Jul; 29(7):535-553. PubMed ID: 31203700
[TBL] [Abstract][Full Text] [Related]
5. Use of dipeptidyl peptidase-4 inhibitors and the risk of arthralgia: Population-based cohort and nested case-control studies.
Wang CY; Fu SH; Yang RS; Hsiao FY
Pharmacoepidemiol Drug Saf; 2019 Apr; 28(4):500-506. PubMed ID: 30724413
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
Thornberry NA; Gallwitz B
Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065
[TBL] [Abstract][Full Text] [Related]
7. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
Singh S; Roy S; Sethi S; Benjamin B; Sundaram S; Khanna V; Kandalkar SR; Pal C; Kant R; Patra AK; Rayasam G; Mittra S; Saini KS; Paliwal J; Chugh A; Ahmed S; Sattigeri J; Cliff I; Ray A; Bansal VS; Bhatnagar PK; Davis JA
Eur J Pharmacol; 2011 Feb; 652(1-3):157-63. PubMed ID: 20540938
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and anti-diabetic activity of triazolotriazine derivatives as dipeptidyl peptidase-4 (DPP-4) inhibitors.
Patel BD; Bhadada SV; Ghate MD
Bioorg Chem; 2017 Jun; 72():345-358. PubMed ID: 28302310
[TBL] [Abstract][Full Text] [Related]
9. Dipeptidyl peptidase-4 inhibitors and risk of arthralgia: A systematic review and meta-analysis.
Men P; He N; Song C; Zhai S
Diabetes Metab; 2017 Dec; 43(6):493-500. PubMed ID: 28778563
[TBL] [Abstract][Full Text] [Related]
10. DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control.
Bae EJ
Arch Pharm Res; 2016 Aug; 39(8):1114-28. PubMed ID: 27502601
[TBL] [Abstract][Full Text] [Related]
11. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
[TBL] [Abstract][Full Text] [Related]
12. DPP-4 inhibitors: a patent review (2012 - 2014).
Costante R; Stefanucci A; Carradori S; Novellino E; Mollica A
Expert Opin Ther Pat; 2015 Feb; 25(2):209-36. PubMed ID: 25482888
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and clinical application of representative small-molecule dipeptidyl Peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus (T2DM).
Shao DW; Zhao LJ; Sun JF
Eur J Med Chem; 2024 Jun; 272():116464. PubMed ID: 38704940
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus patients with severe renal impairment: a meta-analysis.
Chen M; Liu Y; Jin J; He Q
Ren Fail; 2016; 38(4):581-7. PubMed ID: 26915531
[TBL] [Abstract][Full Text] [Related]
15. Potential impact of dipeptidyl peptidase-4 inhibitors on cardiovascular pathophysiology in type 2 diabetes mellitus.
Davidson MH
Postgrad Med; 2014 May; 126(3):56-65. PubMed ID: 24918792
[TBL] [Abstract][Full Text] [Related]
16. Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
Guthrie RM
Postgrad Med; 2015 Jun; 127(5):463-79. PubMed ID: 25956345
[TBL] [Abstract][Full Text] [Related]
17. Impact of dipeptidyl-peptidase 4 inhibitors on cardiovascular diseases.
Xie W; Song X; Liu Z
Vascul Pharmacol; 2018 Oct; 109():17-26. PubMed ID: 29879463
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus.
Chen XW; He ZX; Zhou ZW; Yang T; Zhang X; Yang YX; Duan W; Zhou SF
Clin Exp Pharmacol Physiol; 2015 Oct; 42(10):999-1024. PubMed ID: 26173919
[TBL] [Abstract][Full Text] [Related]
19. Plant dipeptidyl peptidase-IV inhibitors as antidiabetic agents: a brief review.
Turdu G; Gao H; Jiang Y; Kabas M
Future Med Chem; 2018 May; 10(10):1229-1239. PubMed ID: 29749760
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
Scheen AJ
Postgrad Med; 2013 May; 125(3):7-20. PubMed ID: 23748503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
